The departure of a number of major global pharmaceutical brands from the Russian market two years ago gave rise to much anxiety. This concerned whether import substitution would take place, and the fate of Russian partners and counterparties of Western companies. Both those fears were unfounded. Disputes between Russian pharmaceutical companies and foreign ones in the courts have not gone away, but there are not many of them, and they mainly concern patent issues.
“Last year there was a trend toward an increase in the number of patent applications, including for medicines,” adds Olga Nechaeva, a Junior Associate in the Intellectual Property and Information Technologies practice at Nordic Star Law Offices, citing data from the regulator Rospatent. “At the same time, the number of disputes involving foreign companies is decreasing.”
The full version of Olga’s comment can be found on the Business Petersburg website.